SanFran,

Thanks for sharing your story about your mom's benefit for Solanezumab. I'v very happy to hear that she received some benefit from the drug during the time she was on it. For those who haven't seen the news, Eli Lilly is presenting its data this afternoon at the Alzheimer's Association Internation Conference (AAIC) on its EXPEDITION-EXT study, which treats Alzheimer's patients with Solanezumbab, a monoclonal antibody against amyloid-beta. Amyloid beta clumps together to form amyloid plaques, the hallmark of Alzheimers. While some are painting a rosy picture that Solanezumab is effective in the EXPEDITION-EXT trial, others are more reserved and are cautiosly optimisic or negative on these data. Here's a good story on the mixed opinion of the EXPEDITION results. BTW, there's chatter on the BiOasis Stockhouse board today on these monoclonal anti-amyloid beta antibody Alzheimer's therapies if anyone is interested.

OK, here's where I tie this back to Resverlogix and prevent myself from being flagged for off topic. It's been a while since we've heard Resverlogix discuss their mechanism of action/basis for RVX-208 being an Alzheimer's treatmend. RVX is attending the AAIC this week. Can anyone remember what their logic is for RVX-208 being a good candidate for Alzheimer's treatment? Was it the ability of RVX-208 to raise levels of apoAI, and those new apoAI molecules being able to enter the brain and help clear amyloid plaques? I just can't remember right now. Perhaps this would be a timely opportunity for RVX to have an updated blog on their interest in Alzheimers. I glanced through the archive of blog posts and didn't see anything related to Alzheimer's. It would be nice for them to have a blog on their interest in Alzheimer's similar to ones they've released for chronic kidney disease and diabetes.